stockrowRoivant Sciences Ltd.
ROIV Healthcare Biotechnology
Roivant Sciences Ltd.’s revenue for fiscal 2026 (year ended March 2026) was $8.3 million, down 71.6% from fiscal 2025.
- Revenue
- −33.6%
- EPS
- +21.2%
- Free cash flow
- −30.0%
Quarter to June 2026, against a year earlier
Follow ROIV
Alert me
Roivant Sciences Ltd. (ROIV) Current ratio
Roivant Sciences Ltd.'s current ratio at the end of the quarter to 30 June 2026 was 16.7×, down 1.7× from fiscal 2026 (18.4×). Over the past ten years it has ranged from 3.6× (fiscal 2020) to 33.5× (fiscal 2025); the current reading is higher than 71% of that period. That is above the Biotechnology industry median of 4.9× and above the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2026 | 18.4× | (45.10%) |
| FY2025 | 33.5× | 32.61% |
| FY2024 | 25.2× | 282.27% |
| FY2023 | 6.6× | (43.30%) |
| FY2022 | 11.6× | 16.57% |
| FY2021 | 10.0× | 179.16% |
| FY2020 | 3.6× | — |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Jun 2026 | 16.7× | (8.99%) |
| Mar 2026 | 18.4× | (40.08%) |
| Dec 2025 | 30.7× | (9.02%) |
| Sep 2025 | 33.7× | (16.85%) |
| 20 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| ROIV Roivant Sciences Ltd. | 16.7× |
| BNTX BioNTech SE Sponsored ADR compare | 8.6× |
| RVMD Revolution Medicines, Inc. compare | 8.4× |
| INCY Incyte Corporation compare | 3.8× |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 3.6× |
| INSM Insmed, Inc. compare | 2.9× |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 2.5× |
| GMAB Genmab A/S Sponsored ADR compare | 2.5× |
| RPRX Royalty Pharma PLC compare | 1.3× |
| Biotechnology industry median | 4.9× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on ROIV
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement